Keywords: roche, pdl, report, disappointing, zenapax, results, gvhd
Roche And PDL Report Disappointing Zenapax Results In GVHD
Article | 10 July 1995
Hoffmann-La Roche and Protein Design Laboratories have ann-ounced disappointing results of a study using Zenapax (SMART humanized anti-Tac antibody; daclixamab) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
